ArticleJournal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada2026
Treatment of pre-extensively drug-resistant tuberculosis in a critically ill patient using bedaquiline, pretomanid, and linezolid therapy in Canada: A brief report.
Article in Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pre-extensively drug-resistant tuberculosis (pre-XDR-TB) infections are rare in Canada. Drug therapies to treat pre-XDR TB are limited and acquisition of World Health Organization guideline regimens that are not marketed in Canada pose delays in patient care. Our report describes the case of a critically ill patient with pre-XDR TB and their journey to recovery using bedaquiline, pretomanid, and linezolid (BPaL) therapy. Methods: In 2024, a 20-year-old international student from India with no past medical history presented to hospital complaining of respiratory symptoms and had evidence of cavitary findings on chest imaging. While hospitalized, sputum samples reported acid fast bacilli (AFB) on smear. Subsequently, Results: The standard four-drug regimen was initiated after the positive AFB report. Upon staged availability of drug susceptibility results, drug therapy was altered as the strain was resistant to the entire empiric regimen. Due to challenges in the early detection of resistance, the patient clinically worsened resulting in mechanical ventilation. The patient was converted from four-drug intravenous therapy to BPaL therapy obtained through Health Canada's Special Access Program on hospital day 70. The patient reached non-infectious status on hospital day 200. Conclusion: This case highlights clinical challenges encountered in the management of pre-XDR TB in Canada and describes the successful use of BPaL therapy in a mechanically ventilated patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.